Epimutilins, A Novel Class of Oral And IV Antibacterials Overcoming Antimicrobial Resistance
Epimutilins are outstanding novel compounds that are unaffected by antimicrobial resistance to other antibiotic classes and that show potent antibacterial activity against the most prevalent priority pathogens and global health threats as defined by the WHO and CDC.
AR-7732 was selected as the lead compound among a variety of hits within the lead optimization stage. ARIVA Med is about to start the pre-clinical IND enabling studies and to profile this potent compound further.
Various lead-optimization and profiling studies including in vivo proof-of-efficacy and PK studies confirmed AR-2126 as the lead compound. Currently, ARIVA Med is about to start the pre-clinical IND-enabling program.
AR-7013, A Non-Systemic Pleuromutilin in Clinical Stage
Enormously high resistance rates among bacteria causing skin and eye infections drive the high medical need for topical agents that are unaffected by resistance
AR-7013 has demonstrated potent efficacy in vitro and in vivo, minimal systemic exposure, high local tolerance after topical administration to the skin, the eye and the GI tract in animal studies and has shown very good tolerability in human healthy volunteers in a phase 1 clinical trial.
ARIVA Med is actively looking for partners to continue the clinical development of this potent compound that will provide convenient and effective treatment options for patients with skin and eye infections caused by drug-resistant bacteria.